Loading…
← CockpitCompetitor Analysis › 688139.SS Qingdao Haier Biomedical Co., Ltd. Class AOpen in the cockpit ↗

Qingdao Haier Biomedical Co., Ltd. Class A688139.SSCompetitor analysis, valuation and peers

China · CNY·Industrials›Industrial Machinery

Chinese maker of biomedical refrigeration equipment — ultra-low-temperature freezers and vaccine cold-chain systems — part of the Haier Group.

Momentum leader 86
Mkt cap
$1.45B
US dollars, full cap
Free float
43%
of shares outstanding
$/day
$17.7M
20-day average traded
Fwd P/E
33.4×
forward earnings
ROIC−WACC
-2.4 pp
WACC 9.0%
Hurdle
+8 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · CNYCN¥30.36
1D-3.7%
1W-6.5%
1M-6.4%
3M+4.3%
6M-10.6%
YTD-4.5%
1Y-13.2%
ATR %4.3%
52w lowhigh21.8% off high

What Qingdao Haier Biomedical does

Chinese maker of biomedical refrigeration equipment — ultra-low-temperature freezers and vaccine cold-chain systems — part of the Haier Group.

Sells equipment into government-funded programs such as vaccine cold chains, and to labs and hospitals, so demand arrives in procurement waves; it surged during the pandemic vaccine rollouts. Haier Group, the home-appliance maker, is the controlling shareholder.

Products and services

  • Ultra-low-temperature freezers
  • Vaccine refrigerators
  • Lab/blood-bank refrigeration

Customers

  • Hospitals, labs and vaccine distribution networks

Where it sits in the supply chain

  • Health Care
  • Medical/lab equipment
  • Cold-chain refrigeration

What could go right

  • Global vaccine cold-chain and lab-equipment demand

What could go wrong

  • Post-pandemic normalization of vaccine cold-chain demand

Moat: narrow (brand, scale, distribution). Haier Group brand and global distribution scale versus specialized biomedical refrigeration competitors.

Headquarters: Qingdao, China · Founded: 1996 · Employees: 2,945

Named competitors

Qingdao Haier Biomedical at a glance

Size Qingdao Haier Biomedical (688139.SS) is a China Industrials company (Industrial Machinery) with a market value of $1.45B, the 1560th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥30.36 on 18 Nov 2026.

Performance Over six months the shares fell 10.6%, against -26.6% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 12.2% over the last twelve months (peer median +11.8%); the operating margin is 8.6% (peer median 12.9%).

Valuation It trades at 33.4× forward earnings against a peer median of 22.7× (7th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.4 points below its cost of capital (9.0% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026688139.SS 91Peer median 74
Six months, rebased to 100: Qingdao Haier Biomedical against the median of its 20 peers (local-currency closes).

Qingdao Haier Biomedical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.53BCN¥2.32BCN¥2.27BCN¥2.27BCN¥2.84B
Revenue growth—+2%0%-20%—
Gross profitCN¥1.24BCN¥1.00BCN¥1.01BCN¥1.08BCN¥1.32B
EBITDAn/aCN¥302MCN¥404MCN¥395MCN¥608M
Net incomeCN¥272MCN¥251MCN¥367MCN¥406MCN¥601M
Free cash flowCN¥309MCN¥171MCN¥181MCN¥114MCN¥404M
Capital expenditureCN¥90.3MCN¥119MCN¥127MCN¥177MCN¥294M
Total debtCN¥206MCN¥124MCN¥113MCN¥123MCN¥175M

Quarterly statements and history in the cockpit →

Qingdao Haier Biomedical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%0%688543688306INRN3030002164HLIO6880591651CROMPTON300185GDWN688028300171603203LUVE6003430026983013923167688139.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Qingdao Haier Biomedical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×688543688306INRNHLIO68805916513001856880283001716032030026983167688139.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Qingdao Haier Biomedical is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%688306INRN3030HLIO1651CROMPTON300185GDWN300171603203LUVE688139.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Qingdao Haier Biomedical is the large dot.

Qingdao Haier Biomedical competitors and peer comparison

Head to head with its named competitors (688139.SS vs TMO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Qingdao Haier Biomedical 688139.SS$1.45B-11%+12%9%33.4×18.8%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%

How Qingdao Haier Biomedical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Qingdao Haier Biomedical against its 20 peers (data as of 18 Nov 2026)
Measure688139.SSPeer medianRank in peer set
1-month return-6.4%-10.6%7th highest of 21
6-month return-10.6%-26.6%6th highest of 21
Distance from 52-week high-21.8%-45.8%2nd highest of 21
Revenue growth (TTM)+12.2%+11.8%10th highest of 21
Operating margin8.6%12.9%8th lowest of 21
Forward P/E33.4×22.7×7th most expensive of 16
Growth the price implies (Req g, 7 yrs)18.8%9.8%5th most demanding of 14
Growth delivered (Del g)+10.8%+9.8%6th highest of 14
Hurdle (Req g minus delivered)+8.1 pp+1.8 pp5th most demanding of 14
ROIC minus cost of capital-2.4 pp+1.3 pp7th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Qingdao Haier Biomedical 688139.SSChina$1.45B-11%+12%9%33.4×18.8%+10.8%
Jiangxi Guoke Defence 688543.SSChina$1.45B-19%+2%16%44.1×n/an/a
Ningbo PIA Automation 688306.SSChina$1.45B-23%+7%4%159.0×31.7%+8.7%
Interroll INRN.SWSwitzerland$1.44B-8%+2%13%20.2×2.0%-0.6%
Test Research 3030.TWTaiwan$1.46B-45%+32%37%n/a-1.5%+11.3%
Ningbo Donly 002164.SZChina$1.46B+31%+5%5%n/an/an/a
Helios Technologies HLIOUnited States$1.47B-43%+12%13%13.8×9.8%+9.9%
Zhuzhou Huarui Precision Cutting Tools 688059.SSChina$1.47B-32%+23%36%18.5×n/an/a
Precision Tsugami (China) 1651.HKHong Kong$1.47B-42%+25%30%7.0×-17.7%+9.8%
Crompton Greaves Consumer Electricals CROMPTON.NSIndia$1.43B-29%+12%8%22.7×20.0%+11.0%
Tongyu Heavy Industry 300185.SZChina$1.43B-24%+6%4%39.3×5.0%+3.1%
Goodwin GDWN.LUnited Kingdom$1.41B+3%+2%13%n/a47.6%-12.1%
Beijing Worldia Diamond Tools 688028.SSChina$1.40B-48%+22%16%60.2×n/an/a
Tofflon Science and Technology 300171.SZChina$1.40B-3%-2%6%33.5×4.7%+14.0%
Ningbo Haitian Precision Machinery 601882.SSChina$1.50B-21%+19%11%19.4×12.2%+15.6%
Quick Intelligent Equipment 603203.SSChina$1.51B-40%+20%21%37.9×28.0%+15.2%
LU-VE LUVE.MIItaly$1.51B-6%+12%11%24.3×13.9%+8.6%
Shaanxi Aerospace Power Hi-Tech 600343.SSChina$1.38B-58%-15%-24%n/an/an/a
Harbin Boshi Automation 002698.SZChina$1.53B-31%-2%18%17.8×3.9%+9.1%
Guangdong Huicheng Vacuum Technology 301392.SZChina$1.53B-32%+48%7%n/an/an/a
Ta Liang Technology 3167.TWTaiwan$1.54B-15%+122%28%10.6×n/an/a

Questions

Who are Qingdao Haier Biomedical's main competitors?
Named competitors: Thermo Fisher Scientific (TMO), Panasonic Healthcare (private or unlisted). The cockpit's measured peer set (industry) also includes Jiangxi Guoke Defence (688543.SS), Ningbo PIA Automation (688306.SS), Interroll (INRN.SW), Test Research (3030.TW), Ningbo Donly (002164.SZ), Helios Technologies (HLIO).
Is Qingdao Haier Biomedical expensive compared with its peers?
On forward p/e it trades at 33.4× against a peer median of 22.7×, 7th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Qingdao Haier Biomedical stock performed?
Over six months to 18 Nov 2026 the shares returned -10.6% against -26.6% for the median peer; over one year -13.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.